JULY 23, 2021 | EYEWORLD DAILY NEWS | 19
glaucoma@iridex.com • iridex.com/ascrs • Booth 2409
© 2022 Iridex. All rights reserved. Iridex, the Iridex logo, and MicroPulse are registered marks of Iridex. AD0227 04.2022
* 1 Zaarour K, et al. J Glaucoma 2019. 2 Subramaniam K, et al. Cornea 2019. 3 Nguyen AT, et al. Eur J Ophthalmol 2019. 4 Barac R, et a. Romanian J Ophthalmol 2018. 5 Sanchez FG, et al. Arch
Soc Esp Oftalmol 2018. 6 Lee JH, et al. J Glaucoma 2017. 7 Sarrafpour S, et al. Ophthalmology Glaucoma 2019. 8 Awoyesuku EA, et al. JAMMR 2019. 9 Abdelrahman AM, et al. J Glaucoma
2018. 10 Aquino MC, et al. Clin Exp Ophthalmol 2015. 11 Jammal AA, et al. Arq Bras Oftalmol 2019. 12 Tan A, et al. Clin Experiment Ophthalmol 2010. 13 Williams AL, et al. J Glaucoma 2018.
14 Varikuti VNV, et al. J Glaucoma 2019. 15 Souissi S, et al. Eur J Ophthalmol 2019. 16 Magacho L, et al. Lasers Med Sci 2019. 17 Magacho L, et al. J Glaucoma 2019. 18 Yelenskiy A, et al. J
Glaucoma 2018. 19 Aquino MC, et al. European Glaucoma Society 2016.
NON-INCISIONAL GLAUCOMA TREATMENT
MicroPulse® Transscleral Laser Therapy (TLT) is a non-incisional glaucoma procedure that
achieves a success rate of 60% to 80% and IOP reduction of 25% to 45%*. It offers a safe,
effective, and versatile treatment option for various glaucoma types and severities and leaves
future treatment options open. Over 200,000 patients have been treated with it since 2015.
Join us at booth 2409 on Saturday from 1:00 - 2:00 pm and Sunday from 10:00 - 11:00 am to speak with
Dr. Tomás Grippo about MicroPulse TLT — this is an excellent opportunity for one-on-one conversations
about patient selection, technique, dosing, complications, post-op care, outcomes, and durability.
MicroPulse TLT has been a great complement to other glaucoma
treatments in my anterior segment/comprehensive ophthalmology
practice. It is non-incision and complementary to MIGS. I am now
performing several cases per month with excellent results.
"
KEVIN KOVACH, MD
Comprehensive Ophthalmologist, Chicago, IL
"
